Szatmary, Peter
Grammatikopoulos, Tassos
Cai, Wenhao
Huang, Wei
Mukherjee, Rajarshi
Halloran, Chris
Beyer, Georg
Sutton, Robert http://orcid.org/0000-0001-6600-562X
Funding for this research was provided by:
Medical Research Council and National Institute for Health Research (EME 15/20/01)
Innovative Medicines Initiative (821283)
National Institute for Health Research (Senior Investigator Award)
China Scholarship Council (201806240274)
Deutsche Forschungsgemeinschaft (BE 6395-1/1)
National Natural Science Foundation of China (81973632)
Article History
Accepted: 4 August 2022
First Online: 8 September 2022
Declarations
:
: WC is supported by the China Scholarship Council (no. 201806240274) and West China-Liverpool Clinician Scientist Development Award from West China Hospital of Sichuan University. WH is supported by the National Natural Science Foundation of China (no. 81973632). GB is supported by German Research Council (DFG BE 6395-1/1) and the TransBioLine Consortium. RS is supported by an NIHR Senior Investigator Award, an EME Award (15/20/01), an MRC Award (MR/T002220/1) and the TransBioLine Consortium. The TransBioLine project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (Grant agreement no. 821283). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the authors’ view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained therein.
: TG has consulted for Albireo (ongoing). WH has received research funding from Cypralis, Farsight, and Corvidia, with all funds paid to West China Hospital of Sichuan University. RS has consulted for AbbVie CalciMedica, GlaxoSmithKline (GSK), Novartis and Takeda, and has received research funding from CalciMedica, EA Pharma, GSK, Lilly, Merck/MSD, Pfizer as well as multiple public sources in the last three years. RS is collaborating in the IMI2 TransBioLine Consortium with Janssen, Lilly, Merck/MSD, Novartis, Pfizer, Roche, and Sanofi-Aventis. All funds received have been paid to the University of Liverpool and/or Liverpool University Hospitals NHS Foundation Trust.
: This article was written by RS, PS and TG with critical intellectual input from WC, WH, CH and GB. All authors meet the International Committee of Medical Journal Editors criteria for authorship of this paper, take full responsibility for the integrity of the work, and have given their approval for this final version to be published.
: Not applicable.
: All authors have contributed to review and enhancement of the quality of this paper and have reviewed and approved the final version of the manuscript.
: Not applicable.
: Not applicable.